Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice

  • Martos Guillamé, Nerea
  • MOTTO, Aku Enam
  • Gonçalves, Francisco
  • Garcias Ramis, Maria Magdalena
  • Allo-Urzainqui, Estibaliz
  • NARVAEZ BARROS, ALONSO
  • Muñoz Vañó, Vicent
  • León-Román, Juan
  • Vilardell-Vilà, Jordi
  • Vergara, Ander
  • Llorens Cebrià, Carmen
  • Martínez Díaz, Irene
  • Bermejo García, Sheila
  • Ferrer Costa, Roser
  • Jacobs-Cacha, Conxita
  • Soler, María José
Chronic kidney disease; Diabetic kidney disease; Sodium-glucose cotransporter 2 inhibitors, Enfermedad renal crónica; Enfermedad renal diabética; Inhibidores del cotransportador sodio-glucosa 2, Malaltia renal crònica; Malaltia renal diabètica; Inhibidors del cotransportador sodi-glucosa 2, Introduction: Diabetic Kidney Disease (DKD) is the main cause of end-stage renal disease in the developed world. The current treatment of the DKD with renin-angiotensin system (RAS) blockade does not totally halt the progression to end stage kidney disease. Currently, several drugs have shown to delay DKD progression such as sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like-1 receptor agonists (GLP-1RA). We hypothesized that by combining several drugs that prevent DKD progression on top of RAS blockade a synergistic effect would be achieved in terms of cardiorenal protection. In the present study, we analysed if the combination of a RAS blocker (ramipril) with a SGLT2i (empagliflozin) and/or GLP-1RA (semaglutide) in a type 2 diabetic mouse model could have add-on effects in kidney and heart protection. Methods: Male and female uninephrectomized type 2 diabetic db/db mice were treated with empagliflozin and/or semaglutide on top of ramipril during 8 weeks. During the study body weight, water and food intake were weekly monitored, glycaemia biweekly and albuminuria and glomerular filtration rate (GFR) before and after the treatment. At the end of the experiment, kidney and heart were isolated for histological and gene expression studies as well as for intrarenal RAS state assessment. Results: Semaglutide combined with ramipril and/or empagliflozin significantly decreased albuminuria but only when combined with both compounds, semaglutide further decreased blood glucose, glomerular hyperfiltration in male mice and glomerular mesangial matrix expansion. In kidney, only the triple treatment with empagliflozin, semaglutide and ramipril reduced the expression of the proinflammatory and profibrotic genes ccl2 and TGFß1. In addition, the combination of empagliflozin and semaglutide on top of RAS blockade was superior in decreasing cardiomyocyte hypertrophy and heart fibrosis in db/db mice. Discussion: Our results suggest that the combination of SGLT2i with GLP-1RA is superior in cardiorenal protection in DKD than the drugs administered alone on top of RAS blockade., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The study was funded with a grant from Instituto de Salud Carlos III (PI21/01292). JL-R received a Rio Hortega grant from the Instituto de Salud Carlos III (CM23/00213), and IM received a PFIS grant from the Instituto de Salud Carlos III (FI22/00335). The authors are also recipients of other research grants from Instituto de Salud Carlos III (AC22/00029) and the Fundació la Marató de TV3 (202017-10, 202037-31, and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, Drug Delivery and Therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The Apelinergic System in Kidney Disease: Novel Perspectives

  • Saladich-Cavallé, Sara
  • Huo, Linhui
  • Pons Pellicer, Frederic
  • Vilardell-Vilà, Jordi
  • Núñez Delgado, Sara
  • Martínez Díaz, Irene
  • Jacobs-Cacha, Conxita
  • Bermejo García, Sheila
  • Soler, María José
Chronic kidney disease in persons with diabetes; Apelin; Chronic kidney disease, Enfermedad renal crónica en personas con diabetes; Apelin; Enfermedad renal crónica, Malaltia renal crònica en persones amb diabetis; Apelin; Malaltia renal crònica, Chronic kidney disease (CKD) is a major complication of diabetes, affecting approximately 30–40% of patients. In many cases, CKD progresses to end-stage renal disease (ESRD). The peptide apelin and its receptor, APLNR, which is expressed in the endothelial cells of renal blood vessels, play a key role in glucose uptake and the regulation of vasodilation in the afferent and efferent glomerular arterioles. Numerous studies have demonstrated that the apelinergic system is dysregulated in various pathologies, including CKD in people with diabetes. In recent years, the apelinergic system has emerged as a promising therapeutic target for several diseases, with various apelin analogs and inhibitors being developed. In this review, we summarize the most recent literature on apelin and its cellular mechanisms of action, highlighting the role of the apelinergic system in various pathologies and its impact on patients with CKD and diabetes. Additionally, we explore the currently available analogs and inhibitors and discuss their potential therapeutic applications., This study was funded by a research grant from Boehringer Ingelheim. I.M.-D was awarded a PFIS grant from the Instituto de Salud Carlos III (FI22/00335), and L.H. was awarded a China Scholarship Council (CSC) grant. The authors are also recipients of other research grants from Instituto de Salud Carlos III (PI21/01292, AC22/00029, INT23/00078, PI24/01573, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/31 and RD24/0004/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, Drug Delivery, and Therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

The Apelinergic System in Kidney Disease: Novel Perspectives

  • Saladich-Cavallé, Sara
  • Huo, Linhui
  • Pons Pellicer, Frederic
  • Vilardell-Vilà, Jordi
  • Núñez Delgado, Sara
  • Martínez Díaz, Irene
  • Jacobs-Cacha, Conxita
  • Bermejo García, Sheila
  • Soler, María José
Chronic kidney disease in persons with diabetes; Apelin; Chronic kidney disease, Enfermedad renal crónica en personas con diabetes; Apelin; Enfermedad renal crónica, Malaltia renal crònica en persones amb diabetis; Apelin; Malaltia renal crònica, Chronic kidney disease (CKD) is a major complication of diabetes, affecting approximately 30–40% of patients. In many cases, CKD progresses to end-stage renal disease (ESRD). The peptide apelin and its receptor, APLNR, which is expressed in the endothelial cells of renal blood vessels, play a key role in glucose uptake and the regulation of vasodilation in the afferent and efferent glomerular arterioles. Numerous studies have demonstrated that the apelinergic system is dysregulated in various pathologies, including CKD in people with diabetes. In recent years, the apelinergic system has emerged as a promising therapeutic target for several diseases, with various apelin analogs and inhibitors being developed. In this review, we summarize the most recent literature on apelin and its cellular mechanisms of action, highlighting the role of the apelinergic system in various pathologies and its impact on patients with CKD and diabetes. Additionally, we explore the currently available analogs and inhibitors and discuss their potential therapeutic applications., This study was funded by a research grant from Boehringer Ingelheim. I.M.-D was awarded a PFIS grant from the Instituto de Salud Carlos III (FI22/00335), and L.H. was awarded a China Scholarship Council (CSC) grant. The authors are also recipients of other research grants from Instituto de Salud Carlos III (PI21/01292, AC22/00029, INT23/00078, PI24/01573, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/31 and RD24/0004/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, Drug Delivery, and Therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice

  • Martos Guillamé, Nerea
  • MOTTO, Aku Enam
  • Gonçalves, Francisco
  • Garcias Ramis, Maria Magdalena
  • Allo-Urzainqui, Estibaliz
  • NARVAEZ BARROS, ALONSO
  • Muñoz Vañó, Vicent
  • León-Román, Juan
  • Vilardell-Vilà, Jordi
  • Vergara, Ander
  • Llorens Cebrià, Carmen
  • Martínez Díaz, Irene
  • Bermejo García, Sheila
  • Ferrer Costa, Roser
  • Jacobs-Cacha, Conxita
  • Soler, María José
Chronic kidney disease; Diabetic kidney disease; Sodium-glucose cotransporter 2 inhibitors, Enfermedad renal crónica; Enfermedad renal diabética; Inhibidores del cotransportador sodio-glucosa 2, Malaltia renal crònica; Malaltia renal diabètica; Inhibidors del cotransportador sodi-glucosa 2, Introduction: Diabetic Kidney Disease (DKD) is the main cause of end-stage renal disease in the developed world. The current treatment of the DKD with renin-angiotensin system (RAS) blockade does not totally halt the progression to end stage kidney disease. Currently, several drugs have shown to delay DKD progression such as sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like-1 receptor agonists (GLP-1RA). We hypothesized that by combining several drugs that prevent DKD progression on top of RAS blockade a synergistic effect would be achieved in terms of cardiorenal protection. In the present study, we analysed if the combination of a RAS blocker (ramipril) with a SGLT2i (empagliflozin) and/or GLP-1RA (semaglutide) in a type 2 diabetic mouse model could have add-on effects in kidney and heart protection. Methods: Male and female uninephrectomized type 2 diabetic db/db mice were treated with empagliflozin and/or semaglutide on top of ramipril during 8 weeks. During the study body weight, water and food intake were weekly monitored, glycaemia biweekly and albuminuria and glomerular filtration rate (GFR) before and after the treatment. At the end of the experiment, kidney and heart were isolated for histological and gene expression studies as well as for intrarenal RAS state assessment. Results: Semaglutide combined with ramipril and/or empagliflozin significantly decreased albuminuria but only when combined with both compounds, semaglutide further decreased blood glucose, glomerular hyperfiltration in male mice and glomerular mesangial matrix expansion. In kidney, only the triple treatment with empagliflozin, semaglutide and ramipril reduced the expression of the proinflammatory and profibrotic genes ccl2 and TGFß1. In addition, the combination of empagliflozin and semaglutide on top of RAS blockade was superior in decreasing cardiomyocyte hypertrophy and heart fibrosis in db/db mice. Discussion: Our results suggest that the combination of SGLT2i with GLP-1RA is superior in cardiorenal protection in DKD than the drugs administered alone on top of RAS blockade., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The study was funded with a grant from Instituto de Salud Carlos III (PI21/01292). JL-R received a Rio Hortega grant from the Instituto de Salud Carlos III (CM23/00213), and IM received a PFIS grant from the Instituto de Salud Carlos III (FI22/00335). The authors are also recipients of other research grants from Instituto de Salud Carlos III (AC22/00029) and the Fundació la Marató de TV3 (202017-10, 202037-31, and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883). The Clinical Biochemistry, Drug Delivery and Therapy Research Group is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 01173).